Unique ID issued by UMIN | UMIN000051350 |
---|---|
Receipt number | R000058584 |
Scientific Title | Efficacy of angiotensin II receptor blocker versus sacubitril valsartan on Blood pressure and glycemic control measured by continuous glucose monitoring in adults with type 2 diabetes complicated by hypertension |
Date of disclosure of the study information | 2023/06/20 |
Last modified on | 2023/06/15 11:43:15 |
Efficacy of angiotensin II receptor blocker versus sacubitril valsartan on Blood pressure and glycemic control measured by continuous glucose monitoring in adults with type 2 diabetes complicated by hypertension
Efficacy of angiotensin II receptor blocker versus sacubitril valsartan on Blood pressure and glycemic control measured by continuous glucose monitoring in adults with type 2 diabetes complicated by hypertension
Efficacy of angiotensin II receptor blocker versus sacubitril valsartan on Blood pressure and glycemic control measured by continuous glucose monitoring in adults with type 2 diabetes complicated by hypertension
Efficacy of angiotensin II receptor blocker versus sacubitril valsartan on Blood pressure and glycemic control measured by continuous glucose monitoring in adults with type 2 diabetes complicated by hypertension
Japan |
Type 2 Diabetes
Endocrinology and Metabolism |
Others
NO
Verification of superiority of systolic blood pressure and Time In Range at week 16
Safety,Efficacy
Change systolic blood pressure from baseline to week 16
Proportion of Time In Tight Range at Week 16
Others of Glycemic indicator
Change albuminuria from baseline to week 16
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
Central registration
2
Treatment
Medicine |
angiotensin II receptor blocker
Sacubitril Valsaltan
20 | years-old | <= |
Not applicable |
Male and Female
Type 2 diabetes mellitus patients with hypertension over 20 years of age
Patients who have been treated with the maximum dose of angiotensin II receptor blocker
Patients with systolic Blood pressure 135mmHg or more
Patients with HbA1c 6.5% or more and less than 10.5%
Patients diagnosed with type 1 diabetes
Individuals who have a hypersensitivity to Sacubitril valsartan or angiotensin II receptor blockers
History of angioedema
severe renal dysfunction (eGFR < 30 mL/min/1.73 m2)
severe hepatic dysfunction (Child-Pugh classification C)
pregnant women, or individuals who may be pregnant
other patients who the physician deems unsuitable should avoid using this medication.
40
1st name | Yasutake |
Middle name | |
Last name | Shinohara |
Tochigi Medical Center Shimotsuga
Diabetes and Endocrinology
329-4498
420-1Kawatsure,Ohira-machi,Tochigi -city,Japan
0282-22-2551
yasutake@dokkyomed.ac.jp
1st name | Yasutake |
Middle name | |
Last name | Shinohara |
Tochigi Medical Center Shimotsuga
Diabetes and Endocrinology
32-4498
420-1Kawatsure,Ohira-machi,Tochigi -city,Japan
0282-22-2551
yasutale@dokkyomed.ac.jp
Tochigi Medical Center Shimotsuga
NONE
Other
Tochigi Medical Center Shimotsuga
420-1Kawatsure,Ohira-machi,Tochigi -city,Japan
0282-22-2551
yasutake@dokkyomed.ac.jp
NO
2023 | Year | 06 | Month | 20 | Day |
Unpublished
Enrolling by invitation
2023 | Year | 04 | Month | 23 | Day |
2023 | Year | 05 | Month | 24 | Day |
2023 | Year | 06 | Month | 20 | Day |
2024 | Year | 08 | Month | 30 | Day |
2023 | Year | 06 | Month | 15 | Day |
2023 | Year | 06 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000058584